• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease

    9/21/23 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BHC alert in real time by email

    Partnership Aims to Educate Hispanic Communities About the Signs, Symptoms, and Prevalence of Gum Disease

    Collaboration Launches During Hispanic Heritage Month With Activations Featuring Patient Ambassador Alex Rodriguez

    LAVAL, QC / ACCESSWIRE / September 21, 2023 / In honor of Hispanic Heritage Month, Bausch Health Companies Inc. (NYSE:BHC),(TSX:BHC) and its oral health care business, OraPharma, today announced its collaboration with the League of United Latin American Citizens (LULAC) - the largest and oldest Hispanic organization in the United States - to foster a greater understanding of gum disease detection, and treatment within the Hispanic community.

    Gum disease, also known as periodontal disease, is a chronic bacterial infection that affects nearly 65 million American adults and is even more common among Latinos. The most common symptoms of gum disease are bleeding during or after brushing and red or swollen gums. Further, studies show gum disease may be associated with increased risk for other chronic conditions throughout the body such as diabetes and cardiovascular disease, which may considerably affect the Hispanic community.

    This partnership includes LULAC's involvement in supporting the Cover Your Bases campaign, a national awareness initiative featuring patient ambassador and World Series Champion, Alex Rodriguez, who is helping to raise disease awareness by encouraging people to talk to their dentist about their oral health, including screening for gum disease.

    "I'm proud to welcome LULAC to the Cover Your Bases campaign to help educate the Latino community on the importance of identifying the signs and symptoms of gum disease," said Rodriguez. "I was lucky my dentist diagnosed my gum disease early and implemented a comprehensive treatment plan. I hope that by sharing my story I can help more people do the same, especially since we know gum disease is more prevalent in men and within the Latino community."

    OraPharma's work with LULAC includes a range of educational resources featuring Alex Rodriguez that will be distributed across the organization's social and digital channels. OraPharma will also be at LULAC's National Health Summit in Dallas, TX on October 21st to help educate attendees about gum disease and treatment options.

    "As an organization dedicated to advancing the health of the Hispanic population in the United States, LULAC is honored to join hands with OraPharma and Alex Rodriguez to share this important message," said Juan Proaño, LULAC Interim-CEO. "Millions of Hispanic Americans suffer from gum disease, yet many individuals are unaware and undiagnosed. Coupled with the potential associated health risks, gum disease is a chronic condition, so we must help heighten awareness surrounding this condition and arm our members with information that encourages them to take action and talk to their dentist.

    For patients with gum disease, it's important to consider a comprehensive treatment plan to help fight the bacteria that causes gum disease. Like other bacterial infections, a dentist can treat gum disease. A treatment option for adults with gum disease is an antibiotic called ARESTIN® (minocycline HCI), which is used in combination with scaling and root planing (SRP) and applied at the site of infection. ARESTIN is part of an overall oral health program that includes good brushing and flossing habits.

    "As we celebrate Hispanic Heritage Month, OraPharma is proud to partner with respected organizations like LULAC to address gum disease as an often-overlooked health disparity in the Latino community," said Tom Stern, Vice President and General Manager at OraPharma. "Though there is no cure for gum disease, we hope that the mission we're on together will help to bridge the information gap and empower the Hispanic community to take control of their oral health by speaking with their dentist and seeking a treatment plan that may help manage the condition."

    To learn more, visit www.Arestin.com or follow us on Instagram and Facebook.

    About ARESTIN®

    INDICATION

    ARESTIN (minocycline HCl) Microspheres, 1mg is used in combination with scaling and root planing (SRP) procedures to treat patients with adult periodontitis (gum disease). ARESTIN may be used as part of an overall oral health program that includes good brushing and flossing habits and SRP.

    IMPORTANT SAFETY INFORMATION

    • Do not take ARESTIN if you are allergic to minocycline or tetracyclines. Ask your dentist or pharmacist for a list of these drugs if you are not sure. Swelling of the face, itching of the skin, fever and enlarged lymph nodes have been reported with the use of ARESTIN. Some of these reactions were serious. Tell your dentist right away if you have any signs of allergic reaction, such as skin reactions or trouble breathing, or if you have an exaggerated sunburn reaction.
    • THE USE OF TETRACYCLINE CLASS DRUGS, INCLUDING ARESTIN, DURING TOOTH DEVELOPMENT MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH, AND THEREFORE SHOULD NOT BE USED IN CHILDREN OR IN PREGNANT OR NURSING WOMEN.
    • ARESTIN has not been studied in patients with weakened immune systems (such as patients with HIV infections or diabetes, or those receiving chemotherapy or radiation). Tetracyclines, including oral minocycline, have been associated with the development of autoimmune syndrome with symptoms such as joint pain, muscle pain, rash, swelling, fever, enlarged lymph nodes, and general body weakness. Tell your doctor about any health problems you have, including whether you have had oral candidiasis ("thrush") in the past, and about all medications you are taking.
    • In clinical studies, the most frequently reported non-dental side effects were headache, infection, flu symptoms, and pain.

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

    Click here for full Prescribing Information.

    About OraPharma

    OraPharma is a specialty pharmaceutical company committed to partnering with dental professionals to improve oral health. Founded more than 25 years ago, OraPharma includes a curated portfolio of treatments for periodontal disease, and multiple regenerative solutions for oral surgery. More information can be found at https://www.orapharma.com/.

    About Bausch Health

    Bausch Health Companies Inc. (NYSE:BHC),(TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

    About LULAC

    The League of United Latin American Citizens (LULAC) is the nation's largest and oldest Hispanic civil rights volunteer-based organization that empowers Hispanic Americans and builds strong Latino communities. Headquartered in Washington, DC, with 1,000 councils around the United States and Puerto Rico, LULAC's programs, services, and advocacy address the most important issues for Latinos, meeting the critical needs of today and the future. For more information, visit https://lulac.org/

    For Media Inquiries:

    Kevin Wiggins
    corporate.communications@bauschhealth.com
    (908) 541-3785

    Bridget Mackey
    bmackey@coynepr.com
    (973) 588-2169

    SOURCE: Bausch Health Companies Inc



    View source version on accesswire.com:
    https://www.accesswire.com/785609/league-of-united-latin-american-citizens-lulac-joins-orapharma-in-the-fight-against-gum-disease

    Get the next $BHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHC

    DatePrice TargetRatingAnalyst
    12/9/2025$8.00Equal Weight
    Barclays
    8/2/2024$9.00 → $3.00Neutral → Underweight
    Piper Sandler
    7/10/2024$8.00Mkt Perform
    Raymond James
    9/20/2023$9.00 → $16.00Hold → Buy
    Jefferies
    6/16/2023Outperform → Market Perform
    TD Cowen
    7/29/2022Buy → Hold
    Truist
    7/29/2022$12.00 → $5.00Outperform → Sector Perform
    RBC Capital Mkts
    7/28/2022Overweight → Neutral
    JP Morgan
    More analyst ratings

    $BHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Paulson & Co. Inc. bought $15,625,000 worth of shares (2,500,000 units at $6.25) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    11/28/25 5:38:39 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $312,490,062 worth of shares (34,721,118 units at $9.00) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/14/25 9:35:28 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $21,267,731 worth of shares (3,243,049 units at $6.56) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/13/25 6:51:24 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

    LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:                                            Wednesday, April 29, 2026Time:                                            5:00 p.m. U.S. EDTWebcast:                                      http://ir.bauschhealth.com/events-and-

    3/31/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program

    Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with applications open through June 2026LAVAL, QC, March 26, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the 2026 ASPIRE HIGHER Scholarship Program, with applications open through June 10, 2026. The program will award six exceptional students, impacted by dermatologic conditions with scholarships of up to $10,000 each to support their pursuit of higher education. "It is an honor to continue the AS

    3/26/26 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada

    LAVAL, QC, Feb. 23, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today announced the launch of the Clear + Brilliant® Touch laser in Canada. The device was approved by Health Canada on May 20, 2025, marking an important milestone as demand for non‑invasive skin rejuvenation treatments continues to grow across Canada. With this approval, Canadian physicians are able to offer one of the most advanced dual-wavelength laser technologies on the market, expanding access to customizable treatments that align with the country's growing preference for effective yet approachable s

    2/23/26 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    SEC Filings

    View All

    Bausch Health Companies Inc. filed SEC Form 8-K: Leadership Update

    8-K - Bausch Health Companies Inc. (0000885590) (Filer)

    3/2/26 5:17:03 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Companies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Bausch Health Companies Inc. (0000885590) (Filer)

    2/18/26 4:12:11 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Companies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bausch Health Companies Inc. (0000885590) (Filer)

    1/23/26 4:06:26 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Leung Sandra

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    4/2/26 6:30:13 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Paulson John

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    4/2/26 6:20:34 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Wechsler Amy B

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    4/2/26 6:19:05 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Bausch Health with a new price target

    Barclays initiated coverage of Bausch Health with a rating of Equal Weight and set a new price target of $8.00

    12/9/25 8:43:03 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously

    8/2/24 7:25:50 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Bausch Health with a new price target

    Raymond James initiated coverage of Bausch Health with a rating of Mkt Perform and set a new price target of $8.00

    7/10/24 8:35:33 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bausch Health Companies Inc.

    SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

    8/30/24 6:12:52 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Bausch Health Companies Inc.

    SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)

    8/19/24 5:48:41 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Bausch Health Companies Inc. (Amendment)

    SC 13G/A - Bausch Health Companies Inc. (0000885590) (Subject)

    2/13/24 4:30:26 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Leadership Updates

    Live Leadership Updates

    View All

    Bausch Health Appoints New Chief Medical Officer and Head of R&D

    LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,

    12/2/24 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Welcomes Two New Members to the Executive Leadership Team

    LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services, primarily at General Electric, Hewlett Packard, Novartis and Purdue Pharma. Upon JJ's arrival, John Barresi, the Company's Interim Chief Financial Officer, will resume his role as SVP, Controller.Aimee Lenar joined the Company on July 15, 2024 as Executive Vice President, US Pharm

    7/19/24 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day

    BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day. OIC Awareness Day aims to bring awareness to an often-overlooked side effect of opioids. This day will help patients suffering from OIC by breaking down the stigma and silence surrounding this condition."OIC Awareness Day will help bridge the gap between healthcare providers (HCPs), patients, and caregivers by providing

    12/5/23 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Financials

    Live finance-specific insights

    View All

    Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

    LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:                                            Wednesday, April 29, 2026Time:                                            5:00 p.m. U.S. EDTWebcast:                                      http://ir.bauschhealth.com/events-and-

    3/31/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

    Fourth Quarter Consolidated Revenues of $2.80 billion, up 9% on a Reported basis and up 6% on an Organic (non-GAAP)1 basis over the prior year periodFull-Year Consolidated Revenues of $10.27 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basisGAAP Net Loss Attributable to Bausch Health of $112 million for the quarter and GAAP Net Income Attributable to Bausch Health of $157 million for the yearConsolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $1.05 billion for the quarter, up 13%, and $3.54 billion for the year, up 7%BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FOURTH QUARTER AND FULL-YEAR 2025 RESULTSDelivered eleventh consecutive quarter of year-over-y

    2/18/26 4:05:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026

    LAVAL, QC, Jan. 21, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2025 financial results after market close on Wednesday, February 18, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EST to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call. Conference Call Details Date:         Wednesday, February 18, 2026Time:         5:00 p.m. U.S. ESTWebcast:   http://ir.bauschhealth.com/events-and-presentations A replay of the conference call will be available on the investor rel

    1/21/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care